Method for providing information on metachronous recurrence of gastric cancer
By measuring the levels of CD8, CD4, and PD-L1 markers in gastric mucosal tissue, the problem of predicting metachronous recurrence of gastric cancer after endoscopic resection of Helicobacter pylori eradication therapy has been solved, enabling early prediction and personalized management, and improving the effectiveness and cost-effectiveness of treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- IND ACADEMIC COOP FOUND YONSEI UNIV
- Filing Date
- 2024-09-23
- Publication Date
- 2026-07-10
AI Technical Summary
In the current technology, the efficacy of Helicobacter pylori eradication therapy after endoscopic resection in preventing metachronous recurrence of gastric cancer is uncertain, and there is a lack of effective prediction methods, resulting in imperfect follow-up examination strategies.
By measuring the mRNA or protein levels of CD8, CD4, and PD-L1 markers in gastric mucosal tissue, and using methods such as droplet digital polymerase chain reaction (dd-PCR) and reverse transcription polymerase chain reaction (RT-PCR), the likelihood of metachronous gastric cancer recurrence in an individual can be determined.
It provides the possibility of early prediction of gastric cancer recurrence, helps to develop personalized tracking and management strategies, reduces unnecessary examination and treatment costs, and improves treatment outcomes.
Smart Images
Figure CN122374645A_ABST